95 MET ECD shedding and poor DFS Fig. 2: Performance of A2H2-3 across the antibody validation cell line panel. a Immunoreactivities observed for p145N-term. MET (A2H2-3) under nonreducing conditions, immunoreactivities observed for p145C-term. MET (D1C2) under reducing conditions, quantitative real-time PCR (qRT-PCR) results showing average MET fluorescence standardized to average HPRT1 fluorescence. b Negative controls (NCs) and membranous (M), cytoplasmic (C), and nuclear (N) immunohistochemical reactivities observed for A2H2-3 and D1C2. c Observed immunoreactivities using western blotting, mRNA expression levels, and immunoreactivities using immunohistochemistry. *Reference results retrieved from (18). Figure 2a also illustrates that D1C2 and A2H2-3 perform comparably in terms of specificity and sensitivity in the detection of p170 and p145β under reducing and nonreducing conditions. Figure 2b shows that when using immunohistochemistry both antibodies specifically detect cytoplasmic MET with comparable results across all cell lines. Moreover, it shows that although both antibodies specifically detect membranous MET, A2H2-3 has a higher sensitivity compared with D1C2 (PC3 and SK-BR-3). 4
RkJQdWJsaXNoZXIy MTk4NDMw